Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSStructure Therapeutics published full Phase 2b data for aleniglipron, a once-daily oral small molecule, in Nature Medicine. On the top dose, 70 percent of people lost at least 10 percent of their body weight, and the loss kept deepening past 36 weeks.
A pharmacovigilance analysis of 1,618 thrombotic reports filed against GLP-1 drugs from 2020 to 2025 found no excess clotting signal. Reports ran about a third below the rate for an average drug, and lower than orlistat or SGLT2 inhibitors. Voluntary reports cannot prove cause, but the feared alarm did not sound.
A matched study of 18,062 adults over 50 found GLP-1 users had about 85 percent fewer major fractures, plus less osteoporosis and arthritis, than people on other weight-loss drugs. The comparison is relative and observational, but the bone-fragility fear did not show up in the data.
A new subgroup analysis of the FLOW trial split its diabetic kidney-disease patients by cardiovascular status. Semaglutide cut the combined kidney-and-death risk by a similar amount whether patients had clogged arteries, heart failure, or no diagnosed heart disease at all, and every test for a difference came back null. The heart-failure group, usually the hardest to help, needed the fewest patients treated to prevent one kidney event.
Peptide receptor radionuclide therapy won its approval in midgut neuroendocrine tumors. A single-center decade of records in 34 patients with the under-studied foregut and hindgut tumors found an 80 percent disease-control rate, median progression-free survival of 29.7 months, and more than half alive at five years, with serious side effects in only 5 of 34.
A post hoc analysis of SURMOUNT-1 went back to stored blood from 392 participants and measured 17 cardiovascular markers. At 72 weeks the top dose of tirzepatide cut inflammation (hsCRP -54.6 percent), leptin (-61.4 percent), and clotting protein PAI-1 (about -40 percent), and raised protective adiponectin (+47.7 percent), with most effects deepening step by step from 5 to 10 to 15 mg.
A 111,646-woman records study found GLP-1 users were diagnosed with breast cancer roughly a third less often. Propensity matching on BMI, breast density, and diabetes barely moved the estimate, from 0.65 to 0.70.
In obese mice, semaglutide stripped skeletal muscle as it stripped fat and left newly healed fibers undersized. Adding a 15-PGDH inhibitor woke muscle stem cells and recovered strength without slowing the weight loss.
In 12 people with no pancreas, infused GLP-1 cut post-meal glucose 45 percent and slowed gastric emptying, while GIP left glucose untouched but cut bone breakdown 65 percent and raised heart rate. The two incretins behind tirzepatide run separate programs outside the pancreas.
Exendin-4, the peptide behind the diabetes drug exenatide, kept photoreceptors alive in two models of atrophic macular degeneration by reinstating GLP-1R/PKA/CREB1 signaling. Silencing the receptor, blocking PKA, or blocking CREB1 each abolished the rescue.
A new PLOS Pathogens paper screens a porcine cell library against Seneca Valley Virus 3C protease and lands a substrate-competitive decapeptide, P5, that hydrogen-bonds the catalytic His48, prevents 3C from cleaving cGAS, gasdermin A and pro-IL-1 beta, and restores cGAS-DNA phase separation along with downstream type I interferon signaling.
A disproportionality analysis of 3,460 biliary adverse-event reports across five GLP-1 receptor agonists, with semaglutide as the within-class reference, found dulaglutide's cholangitis signal at PRR 1.65, exenatide topping cholelithiasis at 1.33, and meaningful heterogeneity across the class. The standard class-warning summary does not capture it.
Rats given an anti-CGRP migraine antibody fifteen minutes before a subarachnoid hemorrhage had higher cerebral blood flow at five minutes and better motor recovery at forty-eight hours. By two weeks, survival and composite neurology had converged. Early benefit, late wash.
A TriNetX cohort published in the Journal of Clinical Neuroscience matched 261 GLP-1-exposed adults to 261 unexposed controls, all of whom underwent endovascular thrombectomy for acute ischemic stroke, and tracked three-year mortality (11.5 vs 29.9 percent, HR 0.334, 95% CI 0.219-0.508) and inpatient hospitalizations (39.8 vs 54.8 percent, HR 0.514, 95% CI 0.398-0.663). The class-level exposure flag means the signal applies to GLP-1 receptor agonists as a class, not to any one molecule.
A new ODAST study built a lysine-centered branched peptidomimetic against TNF-alpha and ran it through three iterative rounds (charge identity, charge density, aromatic and hydrogen bonding), arriving at a bidentate anionic recognition motif that bound the cytokine more than ten times tighter than the parent scaffold and blocked TNF-alpha-induced cytotoxicity in cells at low-micromolar IC50.